Male Health Drug Development Pipeline Review, 2017
Summary Male hypogonadism is characterized by androgen deficiency and infertility. Hypogonadism can be caused by disorders at the hypothalamic or pituitary level (hypogonadotropic forms) or by testicular dysfunction (hypergonadotropic forms). There are a total of 23 products in development for this indication, by 19 companies and one academic institution. Key companies operating in this pipeline space include Lipocine, M et P Pharma, Repros Therapeutics and TesoRx Pharma.
Erectile dysfunction is defined as the inability to achieve and maintain an erection sufficient to permit satisfactory intercourse. There are a total of 36 products in development for this indication, by 31 companies and two academic institutions. Key companies operating in this pipeline space include Mitsubishi Tanabe Pharma, Futura Medical, Monosol Rx and NAL Pharmaceuticals.
Finally, Benign prostatic hyperplasia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 29 products in development for this indication, by 26 companies and four academic institutions. Key companies operating in this pipeline space include Chong Kun Dang Pharmaceutical, Nymox Pharmaceutical and Yungjin Pharm.
The most common target for male hypogonadism is the androgen receptor, while phosphodiesterase 5 targets dominate the erectile dysfunction pipeline. Targets for the treatment of benign prostatic hyperplasia are more diverse with a strong presence of both androgen receptor and phosphodiesterase targets.
The report, "Male Health Drug Development Pipeline Review, 2017" provides an overview of the male health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Male Hypogonadism, Erectile Dysfunction and Benign Prostatic Hyperplasia and features dormant and discontinued projects.
Scope - Which companies are the most active within the pipeline for male health therapeutics? - Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? - To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? - What are the most important R&D milestones and data publications to have happened in the field of male health?
Reasons to buy - Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication - Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each - Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these - Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Our reports have been used by over 10K customers, including:
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
Melanoma - Global Drug Forecast and Market Analysis to 2029 Summary Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body.Although melanoma has high survivability, it remains a significant health...
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029 Summary Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%.The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification...
Certain factors that are driving the market growth include the increased incidence of cancer, globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development. - Globally,...
Opportunity Analyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025 Summary The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF - Roche’s Esbriet and Boehringer Ingelheim’s Ofev. Esbriet was the first drug to gain approval...
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 Summary Both NASH and NAFLD occur largely as a result of prolonged insulin resistance and obesity with approximately 80% of cases being diagnosed in overweight individuals. NASH...
Digestive System Disorder
Prescription Drug Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.